EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m6A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia

Xiaofang Hong, Daiyan Yang, Jianhao Xing, Huihui Li, Jifu Zheng

Cancer Immunology, Immunotherapy · 2026

DOI: 10.1007/s00262-026-04413-z ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2026. Verfasst von Xiaofang Hong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi P…. Hauptthemen laut MEDLINE: RNA, Long Noncoding, HMGB1 Protein, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Exosomes. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Natural Science Foundation of Jiangxi Province, Science and Technology Plan of Jiangxi Provincial Health Commission.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: MALAT1 has been validated to favor the progression of acute lymphoblastic leukemia (ALL), but its detailed mechanism remains obscure. This study explored the functional roles of ALL cells-derived exosomal MALAT1 in chemoresistance and malignant growth of ALL cells, as well as its underlying mechanisms. METHODS: The expression of target molecules was evaluated by qRT-PCR, Western blotting, immunofluorescence, and immunohistochemical staining. CCK-8, EdU staining and flow cytometry were conducted to determine cell proliferation and apoptosis. RIP, RNA-pull down, Co-IP, and MeRIP were used to investigate molecular mechanisms. ALL cells were injected into nude mice to evaluate in vivo tumor formation. RESULTS: MALAT1 and methyltransferase-like 14 (METTL14) were up-regulated in ALL, which exhibited a positive correlation. METTL14-mediated m6A modification raised MALAT1 stability and expression, and consequently facilitated ALL cell growth and apoptosis inhibition. Furthermore, MALAT1 was packaged into ALL cells-derived exosomes by hnRNPA2B1, and then transferred to NK92-MI cells. Exosomal MALAT1 suppressed tripartite motif-containing 27 (TRIM27)-mediated ubiquitination of High-mobility group box 1 (HMGB1) in NK92-MI cells, thereby leading to adriamycin resistance and malignant development of ALL cells. CONCLUSION: ALL cells-derived exosomal MALAT1 was up-regulated by METTL14-mediated m6A modification, and subsequently restrained HMGB1 ubiquitination and degradation in NK92-MI cells, which resulted in adriamycin resistance and malignant growth of ALL cells. Therefore, inhibition of METTL14/MALAT1/HMGB1 axis might be a therapeutic strategy for ALL patients. HIGHLIGHTS: (1) METTL14 and MALAT1 were positively correlated in ALL samples. (2) METTL14 increased MALAT1 stability and expression in an IGF2BP1-mediated m6A manner. (3) ALL cells transferring exosomal MALAT1 suppressed TRIM27-mediated HMGB1 ubiquitination in NK92-MI cells. (4) HMGB1 silencing in NK92-MI cells enhanced adriamycin sensitivity of ALL cells. (5) MALAT1/HMGB1 axis inhibition delayed in vivo ALL growth via NK cell activation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RNA, Long NoncodingHMGB1 ProteinPrecursor Cell Lymphoblastic Leukemia-LymphomaExosomesHumansAnimalsMiceUbiquitinationCell Line, TumorMice, NudeCell ProliferationApoptosisRNA MethylationAdenosineDrug Resistance, NeoplasmFemaleGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Acute lymphoblastic leukemiaAdriamycin resistanceHMGB1MALAT1METTL14

Substanzen

RNA, Long NoncodingHMGB1 ProteinMALAT1 long non-coding RNA, humanHMGB1 protein, humanAdenosine

Autor:innen und Institutionen

  • Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi Province, China.
  • Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang, 330006, Jiangxi Province, China.
  • Department of Hematology, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, No. 1 Minde Road, Nanchang, 330006, Jiangxi Province, China. ncjeff@163.com.
  • Jiangxi Provincial Key Laboratory of Hematological Diseases, Nanchang, 330006, Jiangxi Province, China. ncjeff@163.com.

Förderung

  • Natural Science Foundation of Jiangxi Province
  • Science and Technology Plan of Jiangxi Provincial Health Commission

Zitieren

APA

Hong, X., Yang, D., Xing, J., Li, H., & Zheng, J. (2026). HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m6A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04413-z

Vancouver

Hong X, Yang D, Xing J, Li H, Zheng J. HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m6A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia. Cancer Immunology, Immunotherapy. 2026. doi:10.1007/s00262-026-04413-z

BibTeX
@article{Hong2026,
  author = {Hong, Xiaofang and Yang, Daiyan and Xing, Jianhao and Li, Huihui and Zheng, Jifu},
  title = {HMGB1 ubiquitination inhibition and extracellular secretion, mediated by m6A modified-exosomal lncRNA MALAT1, creates a communication between NK92-MI cells and tumor cells to aggravate acute lymphoblastic leukemia},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2026},
  doi = {10.1007/s00262-026-04413-z}
}
Kostenlos starten →